Orchid receives USFDA approval for Zaleplon capsules
18 Sep 2009
Orchid Chemicals & Pharmaceuticals has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Zaleplon capsules, 5mg and 10mg.
Zaleplon capsules are used for treating insomnia.
The company has also received approval for its Piperacillin and Tazobactam injections for the treatment of bacteria infections.
The total ANDA approval count of Orchid has now gone up to 37 while the total ANDA filings stand at 58.
Set up in 1992, Orchid Chemicals & Pharmaceuticals commenced operations in 1994. A 100 per cent export oriented unit, Orchid currently employs over 4,200 people, of which over 700 are scientists, technologists and other professionals.
Orchid has two manufacturing sites for APIs at Alathur near Chennai and at Aurangabad, near Mumbai. It has three manufacturing sites for dosage forms at Irungattukottai and Alathur in Chennai, besides two R&D centres at Sholinganallur and Irungattukottai, Chennai.
